Literature DB >> 18095286

The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.

R J Bryant1, S J Winder, S S Cross, F C Hamdy, V T Cunliffe.   

Abstract

BACKGROUND: The Polycomb Group protein EZH2 is implicated in prostate cancer progression. EZH2 promotes prostate cancer cell proliferation and invasiveness. We describe a link between EZH2 function and actin polymerization in prostate cancer cells.
METHODS: Nuclear and cytoplasmic EZH2 expression in benign and malignant prostate tissue samples was assessed. An association between EZH2 function and actin polymerization in prostate cancer cells was investigated using siRNA-mediated knock-down of EZH2. Effects of EZH2 knock-down on actin polymerization dynamics were analyzed biochemically using immunoblot analysis of cell lysate fractions, and morphologically using immunocytochemistry.
RESULTS: Cytoplasmic EZH2 is expressed at low levels in benign prostate epithelial cells and over-expressed in prostate cancer cells. Cytoplasmic EZH2 expression levels correlate with nuclear EZH2 expression in prostate cancer samples. Knock-down of EZH2 in PC3 prostate cancer cells increases the amount of F-actin polymerization, cell size, and formation of actin-rich filaments.
CONCLUSIONS: Cytoplasmic EZH2 is over-expressed in prostate cancer cells. EZH2 function promotes a reduction in the pool of insoluble F-actin in invasive prostate cancer cells. EZH2 may regulate actin polymerization dynamics and thereby promote prostate cancer cell motility and invasiveness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18095286     DOI: 10.1002/pros.20705

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

Review 1.  Histone modifications and chromatin organization in prostate cancer.

Authors:  Zhong Chen; Liguo Wang; Qianben Wang; Wei Li
Journal:  Epigenomics       Date:  2010-08       Impact factor: 4.778

Review 2.  MicroRNAs as putative mediators of treatment response in prostate cancer.

Authors:  Fardod O'Kelly; Laure Marignol; Armelle Meunier; Thomas H Lynch; Antoinette S Perry; Donal Hollywood
Journal:  Nat Rev Urol       Date:  2012-05-22       Impact factor: 14.432

3.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

4.  Overexpression of enhancer of zeste human homolog 2 (EZH2) gene in human cytomegalovirus positive glioblastoma multiforme tissues.

Authors:  Narges Ahani; Reza Shirkoohi; Mohammad Rokouei; Majid Alipour Eskandani; Abbas Nikravesh
Journal:  Med Oncol       Date:  2014-10-08       Impact factor: 3.064

5.  Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.

Authors:  Te Liu; Fuhui Xu; Xiling Du; Dongmei Lai; Tianjin Liu; Yarui Zhao; Qin Huang; Lizhen Jiang; Wenbin Huang; Weiwei Cheng; Zhixue Liu
Journal:  Mol Cell Biochem       Date:  2010-03-12       Impact factor: 3.396

Review 6.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

7.  ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Authors:  Paolo Kunderfranco; Maurizia Mello-Grand; Romina Cangemi; Stefania Pellini; Afua Mensah; Veronica Albertini; Anastasia Malek; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

Review 8.  PRC2 during vertebrate organogenesis: a complex in transition.

Authors:  Issam Aldiri; Monica L Vetter
Journal:  Dev Biol       Date:  2012-05-04       Impact factor: 3.582

9.  Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.

Authors:  Breanne D W Karanikolas; Marxa L Figueiredo; Lily Wu
Journal:  Mol Cancer Res       Date:  2009-09-01       Impact factor: 5.852

10.  EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.

Authors:  Juraj Adamik; Sree H Pulugulla; Peng Zhang; Quanhong Sun; Konstantinos Lontos; David A Macar; Philip E Auron; Deborah L Galson
Journal:  J Bone Miner Res       Date:  2019-10-23       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.